Footnotes

• Correction notice This article has been corrected since it published Online First. The competing interest statement has been amended and the author Sean Lavine's name corrected.

• Competing interests JM: consultant – Lazurus Effect, Reverse, Pulsar, Edge Therapeutics, Medina; investor – Blockade Medical, Medina, Lazurus Effect. ASA: research support – Sequent and Siemens; consultant – Microvention, Johnson and Johnson, Medtronic, Penumbra, Silk Road, Stryker, Sequent; stock – Lazarus Effect and Valor. DF: consultant – Medtronic/Covidien, Stryker, Penumbra, Codman, Siemens. RDT: consultant – Penumbra, Covidien/Medtronic, Codman, Blockade, Pulsar vascular, Microvention. AT: consultant and research grant – Stryker, Penumbra, Microvention; research grant – Medtronic; consultant and shareholder – Medina Medical, Lazarus Effect, Pulsar Vascular. AHS: consultant – Codman & Shurtleff Inc, Covidien Vascular Therapies, GuidePoint Global Consulting, Penumbra, Stryker, Pulsar Vascular, Microvention, Lazarus Effect, Blockade Medical, Reverse Medical, WL Gore & Associates, Medina Medical, Cervetech Inc, Neuroavi, Perflow Medical, Silkroad Medical, TRES Medical, Syntervention; research grants – The National Institutes of Health; financial interests – Hotspur, Intratech Medical, StimSox, Valor Medical, Blockade Medical, Lazarus Effect, Pulsar Vascular, Medina Medical Inc; national steering committees – Penumbra, 3D Separator Trial, Covidien, SWIFT PRIME Trial, LARGE Trial, POSITIVE Trial, Codman, BRAVO Trial, Neuroavi, ARISE II Trial; advisory board – Codman & Shurtleff, Covidien Neurovascular, Inter-societal Accreditation Commission. WJM: consultant – Medtronic (DSMB), Penumbra (DSMB), Lazarus Effect. AA: speaker bureau – Genentech. JAH: consultant – medtronic; shareholder – Intratech.

• Provenance and peer review Commissioned; internally peer reviewed.